This event has run. Thank you to our speakers, sponsors, and delegates who joined us for the 2026 summit.

Radiopharm Doses First Patient in Phase I Prostate Cancer Radiotherapy Study
Alpha‑Emitting PSMA Therapies Gain Momentum Across Radiopharma Leaders
Ratio Therapeutics Highlights the Next Wave of Radiopharmaceutical Manufacturing Standards
Radiopharma Veterans From Novartis‑Built Platforms Strengthen Emerging Biotechs
Radiopharma Takes Center Stage as Global Biopharma Partnering Accelerates

Lead Optimization: TRPV6-Targeted Radioligand Therapy & SAR Analysis for Optimal Ligand Decision Making

Lead Optimization: TRPV6-Targeted Radioligand Therapy & SAR Analysis for Optimal Ligand Decision Making

11:00 am - Thursday 23rd July 2026

Characterization of a novel target that expressed in several solid tumors
Structure Activity Relationship (SAR) analysis in choosing best ligand to take into a Phase 0 clinical trial

Speakers:

Michael Groaning

Chief Scientific Officer

Soricimed Biopharma Inc.